Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.36 |
| ▸ | LATS1 | O95835 | 4/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 4/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12045006 | 1.00 | LMNA (0.40) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29959182 | 1.00 | LMNA (0.40) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12045002 | 0.86 | LMNA (0.39) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2607319 | 0.80 | LMNA (0.53) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27317248 | 0.80 | HTT (0.41) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2607435 | 0.79 | ADRA2A (0.44) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29875062 | 0.79 | ADRA2A (0.44) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12789725 | 0.77 | CYP1A2 (0.40) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20990532 | 0.77 | HASPIN (0.38) | LMNAKDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20315030 | 0.76 | RPS6KA3 (0.42) | LMNAKDM4ECYP1A2MAPKAPK2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | LMNA 4849/4885KDM4E 2772/4885CYP1A2 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.